Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Accumulated Expenses (2016 - 2022)

ProQR Therapeutics' Accumulated Expenses history spans 3 years, with the latest figure at $8.9 million for Q4 2022.

  • On a quarterly basis, Accumulated Expenses fell 28.0% to $8.9 million in Q4 2022 year-over-year; TTM through Dec 2022 was $8.9 million, a 28.0% decrease, with the full-year FY2022 number at $8.9 million, down 30.4% from a year prior.
  • Accumulated Expenses hit $8.9 million in Q4 2022 for ProQR Therapeutics, down from $12.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PRQR hit a ceiling of $12.3 million in Q4 2021 and a floor of $7.3 million in Q4 2020.
  • Historically, Accumulated Expenses has averaged $9.5 million across 3 years, with a median of $8.9 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 68.75% in 2021 and later dropped 28.0% in 2022.
  • Tracing PRQR's Accumulated Expenses over 3 years: stood at $7.3 million in 2020, then surged by 68.75% to $12.3 million in 2021, then dropped by 28.0% to $8.9 million in 2022.
  • Business Quant data shows Accumulated Expenses for PRQR at $8.9 million in Q4 2022, $12.3 million in Q4 2021, and $7.3 million in Q4 2020.